ESPE2021 ePoster Category 2 Growth hormone and IGFs (31 abstracts)
Linear growth of prepubertal children born small for gestational age on growth hormone therapy for 3 years
Adnan Al Shaikh 1 , Hadeer Daftardar 1 , Abdul Aziz Alghamdi 1 , Majd Jamjoom 1 , Saniah Awidah 1 , Mohamed E Ahmed 1 & Ashraf Soliman 2
1King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia; 2University of Alexandra, Alexandria, Egypt
Introduction: Recombinant growth hormone (GH) is an effective treatment for short children who are born small for gestational age (SGA). Short children born SGA who fail to demonstrate catch-up growth by 2-4 years of age are candidates for GH treatment initiated to achieve catch-up growth to a normal height in early childhood, maintain a normal height gain throughout childhood, and achieve an adult height within the normal target range. However, some children who were SGA present during late childhood with short stature.
Aim and Methods: We evaluated the growth patterns before and after the 3 years of growth hormone treatment for 22 children who presented during late childhood with short stature and were born SGA. No dysmorphic features were observed in this group of children. They received 0.035 mg of HGH daily and the dose was adjusted to keep IGFSDS > 0 and <2. Growth hormone (GH) treatment (0.035 mg/kg/day) was initiated at the mean age of 7.9±2.2 years. Their bone age was 6.8 +/- 0.9 years at the start of GH therapy (1.1 +/- 0.8 delayed compared to chronological ages).
Results: Height SDS (HtSDS) increased yearly from −3 SDS after the first year to −1.2 SDS after 3 years of treatment. Their BMI SDS after treatment decreased by 0.9 SD versus before treatment. (table). Increased intracranial pressure was recorded in one child which necessitated discontinuation of GH treatment. None of the children had delayed or precocious puberty during GH therapy.
| Age 1-y | BMISDS1 | HtSDS1 | Age 2 (y) | HtSDS2 | F Age- y | BMI F SDS | HtSDS F | Delta HTSDS | Delta BMI SDS |
| 7.9 | -1.02 | - 3 | 9.2 | -2.3 | 11.5 | -1.9 | -1.2 | 1.8 | -0.89 |
| 2.2 | 1.75 | 1.1 | 2.7 | 1.06 | 2.4 | 1.18 | 1.18 | 1.1 | 1.3 |
| 1 = before treatment, 2 = after a year of treatment, 3 = after 3 years of treatment | |||||||||
Conclusions: We present 22 short prepubertal children who were born SGA, with no dysmorphic features. Treatment with GH for 3 years had increased growth velocity, and all had entered the normal growth range on their growth charts. No significant side-effects were observed in the majority (21/22) of these children during therapy.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more